About Formosa Pharmaceuticals

Business Strategy & Core Competence

Formosa Pharma’s foundation is based on more than 50 years’ combined academic and industrial drug discovery and medicinal chemistry experience, led by Dr. C.Y. Cheng and Dr. Erick Co. Formosa Pharma explores novel programs and the in-licensing of promising development candidates.

Our 2017 acquisition of Activus Pharma, Japan, has afforded us the APNT™ platform, a unique nanoparticle technology for organic molecules of low water-solubility, and two nanoparticle ophthalmology drugs with 505(b)(2) opportunities. The APNT™ platform will continue to provide opportunities for in-house development or co-development with originators of small molecule drugs exhibiting poor bioavailability.

Formosa Pharma’s flagship asset, APP13007, which is co-developed with AimMax Therapeutics, has demonstrated our development success and validated the APNT™ platform.

Development Pipeline

Scroll to Top